Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Oct 26;4(10):e7620. doi: 10.1371/journal.pone.0007620

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Bhattacharyya et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.

PMC Copyright notice

Lesional skin biopsies were obtained from patients with scleroderma (n = 6) and healthy controls (n = 3), and processed for immunohistochemistry as described under Methods. A. Nab2 expression. Skin biopsies from healthy controls (a, b, e) and scleroderma patients (c, d, f, g, h–l). Original magnification ×100(a, h), ×400 (b, d, i), ×630 (c, e, f, j, k, l). Note uniformly intense Nab2 nuclear immunoreactivity in epithelial cells in scleroderma skin biopsies (h, i, l), as well as in perifollicular and periglandular (c, d, g) epithelial cells and vascular endothelial cells (f, j), compared to weak and variable Nab2 expression seen in occasional dermal fibroblasts (k, l). Representative photomicrographs; similar immunostaining pattern was observed in all six scleroderma skin biopsies. B. Phospho-Smad2 (a–d) or Egr-1 (e–h) expression. Nuclei are counterstained with hematoxylin (blue). Note strong immunostaining in dermal fibroblasts in scleroderma (d, h) skin biopsies compared to healthy controls (b, f).